Evotec SE today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec’s second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-accelerates-access-to-biologic-therapeutics-with-initiation-of-manufacturing-facility-in-toulouse-6051
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
Evotec SE announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-partnership-with-kazia-therapeutics-for-clinical-development-of-evt801-6049
Evotec launches “beLAB2122”, translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
Evotec SE announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company. beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-launches-belab2122-translating-academic-innovation-from-leading-german-life-science-region-in-collaboration-with-bristol-myers-squibb-6047
Evotec and Exscientia announce start of human clinical trials of novel immuno-oncology drug
Evotec SE today announced the most advanced asset arising from their joint venture with Exscientia has entered human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed between Exscientia and Evotec, including application of Exscientia’s next generation 3-D evolutionary AI-design platform, Centaur Chemist®. The drug candidate has potential for best-in-class characteristics, with high selectivity for the target receptor, bringing together potential benefits of reduced systemic side effects as well as minimal brain exposure to avoid potential undesired centrally-mediated side effects. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-exscientia-announce-start-of-human-clinical-trials-of-novel-immuno-oncology-drug-6045
The Science Pool: Evotec’s New Scientific Content Hub
Knowledge sharing within the scientific community is a key focus for Evotec. Sharing resources will help to collectively advance R&D and accelerate innovation – ultimately leading to new technology and therapies reaching the market faster. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/the-science-pool-evotecs-new-scientific-content-hub-6043
Evotec SE fiscal year 2020 results: Gaining speed on the "data-driven R&D Autobahn to Cures"
Very strong financial results: 12% increase in Group revenues beating guidance despite pandemic; unique innovation platforms and infrastructure support long-term growth in all modalities; solid balance sheet, strong foundation for next expansion steps Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-fiscal-year-2020-results-gaining-speed-on-the-data-driven-rd-autobahn-to-cures-6042
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Evotec SE today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-takeda-enter-strategic-rna-targeting-drug-discovery-and-development-alliance-6038
Evotec SE to announce results for fiscal year 2020 on 25 March 2021
Evotec SE will announce its financial results for 2020 on Thursday, 25 March 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-announce-results-for-fiscal-year-2020-on-25-march-2021-6034
CMO Leadership Awards 2021
Evotec announces that the Company has been selected as a winner of a 2021 CMO Leadership Award in the categories Compatibility (Big Pharma), Expertise (Big Pharma), and Service (Overall, Small Pharma) Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/cmo-leadership-awards-2021-6036
G-CON Manufacturing and Just – Evotec Biologics Complete the Installation of Cleanroom PODs® for the First J.POD® Facility in North America
Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/g-con-manufacturing-and-just—evotec-biologics-complete-the-installation-of-cleanroom-podsr-for-the-first-jpodr-facility-in-north-america-6032